A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-022759-42

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objectives are: - To evaluate the efficacy of IV induction regimens of Ustekinumab in inducing clinical response in subjects with moderately to severely active Crohn’s disease. - To evaluate the safety of IV induction regimens of Ustekinumab in subjects with moderately to severely active Crohn’s disease.


Critère d'inclusion

  • Moderately-to-Severely Active Crohn’s Disease